Navigation Links
Abbott Donates Diagnostic Instruments As Part of the 'Labs Are Vital(TM)' Initiative
Date:7/30/2008

WASHINGTON, July 30 /PRNewswire-FirstCall/ -- Abbott today announced the recipients of the Labs Are Vital(TM) instrument donation program today at the American Association of Clinical Chemistry (AACC) Annual Meeting.

Recipients were Northern Michigan University, Marquette Mich.; University of Nevada, Las Vegas, Nev.; University of Vermont, Burlington, Vt., Texas State University, San Marcos, Texas, Reading Area Community College, Reading, Penn., Southeastern Community College, Whiteville, N.C.; and Western Technical College, LaCrosse, Wis.

Donated instruments included Abbott's AxSYM(R) automated immunoassay analyzer, CELL-DYN(R) hematology instruments and the i-STAT(R) hand-held point-of-care system.

To date, Abbott has donated more than $3 million in instruments, reagents and service to accredited clinical laboratory education programs across the country. Fifty educational programs, impacting 3,000 students in 29 states within the U.S., received state-of-the-art equipment including immunoassay analyzers, hematology systems, and handheld point-of-care diagnostic instruments.

About Labs Are Vital(TM)

"Labs Are Vital(TM)" is a multi-pronged, multi-year global education and awareness initiative designed to highlight the critical role that laboratory professionals play in health care and to address the issues facing laboratories today. The program -- which includes a public awareness campaign, an instrument donation program and a variety of web-based resources for laboratory professionals -- focuses attention on the life-saving work medical laboratory scientists provide in diagnosing disease and improving health outcomes. For more information on the "Labs are Vital(TM)" program, please visit http://www.labsarevital.com.

The AACC Annual Meeting is a global meeting that attracts nearly 20,000 attendees from more than 100 countries.

About Abbott's Diagnostics Businesses

Abbott is a global leader in in vitro diagnostics and offers a broad range of innovative instrument systems and tests for hospitals, reference labs, molecular labs, blood banks, physician offices and clinics. With more than 65,000 institutional customers in more than 100 countries, Abbott's diagnostic products offer customers automation, convenience, bedside testing, cost effectiveness and flexibility. Abbott has helped transform the practice of medical diagnosis from an art to a science through the company's commitment to improving patient care and lowering costs. The history of Abbott is filled with examples of first-of-a-kind diagnostic products and significant technological and research advancements.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.


'/>"/>
SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Novel Diagnostic Marker for Acute Kidney Injury Previewed at Abbott-Sponsored Scientific Workshop
2. Abbott Fund and the Government of Tanzania Celebrate Milestone in Strengthening Nations Health Care System
3. Abbott to Preview New CELL-DYN(R) Emerald(TM) Hematology Instrument
4. Abbott and Partnership for a Drug-Free America Launch Not In My House to Help Parents Secure Their Homes from Teen Prescription Drug Misuse and Abuse
5. Data Show that Abbotts HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
6. Abbott Opens New State-of-the-Art R&D Facility to Help Bring Medicines to Patients Faster
7. Now Playing: Spike Lee Stands with Earvin Magic Johnson, Cookie Johnson and Abbott to Launch National PSA Campaign
8. American Diabetes Association Receives $450,000 Grant From Abbott Fund for Latino Community Initiatives
9. Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care
10. Abbott Submits Application for Approval of XIENCE(TM) V Everolimus Eluting Coronary Stent System in Japan
11. Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 2016 , ... It is vital for any lab to secure funding, and ... team at Beckman Coulter has designed Kaluza, templates with advanced analytical tools to streamline ... operate in a GLP (Good Laboratory Practice) fashion. , With features designed to simplify ...
(Date:12/7/2016)... ... ... came time to blow out his candles on his 14th birthday, Estefano Reano had only ... team at Joe DiMaggio Children’s Hospital surprised his family with a phone call that made ... , “He was playing at home, when we got the phone call telling us there ...
(Date:12/7/2016)... ... ... One of two inventors from Glen Burnie, Md., has a granddaughter who ... is why the co-inventor and I have designed a new and better way to ... of the patent-pending AV-AIR, a device that serves as an alternative to conventional methods ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... that its fully redesigned website, which launched October 17, 2016, features comprehensive information ... design and easy-to-navigate layout. Visitors and patients can discover the latest clinical dermatology ...
(Date:12/7/2016)... City, CA (PRWEB) , ... December 07, 2016 , ... ... during the holidays and winter seasons. One major study analyzing heart attacks among ... compared to August of a given year. We would all agree of course–no time ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... PARK , Israel , December 7, 2016 ... today the signing of a memorandum of understanding with Korean company ... between the companies will assist in expediting Kadimastem,s entry into international ... innovative treatment for severe diseases in general and ALS and diabetes ... , , ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer Ingelheim ... in patients with unresectable malignant pleural mesothelioma (MPM) ... The data, presented at the 17 th ... Vienna , showed nintedanib plus pemetrexed/cisplatin ... plus pemetrexed/cisplatin, with a significantly improved PFS (9.4 ...
(Date:12/7/2016)... , Dec. 7, 2016  Ionis Pharmaceuticals, Inc. (NASDAQ: ... will present a company overview at the BMO Capital Markets Prescriptions ... New York, NY . A live webcast of ... of the Ionis website.  The replay will be available within 48 ... ...
Breaking Medicine Technology: